Martikainen, Laura

English

UEF Electronic Publications

(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos 30:235-239.

(2003a) A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome

(2004a) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

(2004b) Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.

(2009a) New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.

(2009a) Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

(2009b) Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4.

A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 31:967-971.

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Acetone catabolism by cytochrome P450 2E1: studies with CYP2E1-null mice.

Activation o f C Y P 3 A 4 : e v i d e n c e f o r t h e s i m u l t a n e o u s b i n d i n g o f t w o s u b s t r a t e s i n a c y t o c h r o m e

Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2.

Alhava E and Poso A

Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. Drug Metab Dispos

Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling.

Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics.

Application of cytochrome P450 drug interaction screening in drug discovery.

Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol 5:579-605.

Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos

Bioavailability and pharmacokinetics of oxazepam.

Biochemistry and molecular biology of the human CYP2C subfamily.

Chadwick A and Houston JB (2007) Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 30:86-95.

Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity.

Comparative analysis of binding affinities between styrene and mammalian CYP2E1 by bioinformatics approaches.

Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.

Comparison of heme environment at the putative distal region of P-450s utilizing their external and internal nitrogenous ligand bound forms.

Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.

Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 9:530-537.

Computational models for predicting interactions with cytochrome p450 enzyme.

Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations.

Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order. Drug Metab Rev 43:409-439.

CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention.

Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab Rev

Cytochrome p450 in silico: an integrative modeling approach.

Cytochrome P450 in silico: An integrative modeling approach. J Med Chem. 48:2725-2755 G r a m L F , H a n s e n M G , S i n d r u p S H , B r o s e n K , P o u l s e n J H , A a e s - J o r g e n s e n T a n d O v e r o

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Cytochrome P4502E1 (CYP2E1) expression in peripheral blood lymphocytes: evaluation in hepatitis C and diabetes.

Cytochromes P450 and metabolism of xenobiotics.

Design and application of fluorometric assays for human cytochrome P450 inhibition.

Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today

Development and validation of a genetic algorithm for flexible docking.

Differential effects of naturally occurring isothiocyanates on the activities of cytochrome

Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome P4502E1. Biochem Biophys Res Commun 288:1047-1051. An dri co pu l o AD , S a l u m L B a nd A b ra ha m

Drug interaction studies: study design, data analysis and implications for dosing and labeling (draft)

Drug interactions evaluation: an integrated part of risk assessment of therapeutics.

Drug Interactions, 6th Edition.

Drug interactions. Drug Metab Rev

Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov

Drug-drug interaction profiles of proton pump inhibitors.

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.

Effect of 17-alphaethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites.

Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450.

Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.

Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery.

Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

Fluorometric high-throughput screening for inhibitors of cytochrome P450.

Fluoxetine inhibition of phenytoin metabolism.

Fluoxetine, a selective inhibitor of serotonin uptake.

Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydoxylase, P4502C19.

Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis.

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos

Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems.

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.

High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.

Highly miniaturized formats for in vitro drug metabolism a s s a y s u s i n g v i v i d f l u o r e s c e n t s u b s t r a t e s a n d r e c o m b i n a n t h u m a n c y t o c h r o m e

Human cytochrome P-450 3A4: in vitro drugdrug interaction patterns are substrate-dependent. Drug Metab Dispos

Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode.

Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos

Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues.

Improved protein-ligand docking using GOLD.

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.

In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.

In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos

In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

In vitro methods in the prediction of kinetics of drugs: focus on drug metabolism.

In vitro screening of drug metabolism during drug development: can we trust the predictions? Expert Opin Drug Metab Toxicol 1:49-59.

In vitro tests for predicting drug-drug interactions: the need for validated procedures.

In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos

In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Induction of rat hepatic Nnitrosodimethylamine demethylase by acetone is due to protein stabilization.

Inhibition and induction of human cytochrome P450 enzymes: current status.

Inhibition by ticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine.

Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. Br J Clin Pharmacol 38:9-14. S a c h s e C , B r o c k m o l l e r J , B a u e r S a n d R o o t s

Inhibition of human cytochrome P450 2E1 by halogenated anilines, phenols, and thiophenols.

Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.

Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.

In vitro and in silico methods to predict cytochrome P450 enzyme inhibition

http://epublications.uef.fi/pub/urn_isbn_978-952-61-0755-4/urn_isbn_978-952-61-0755-4.pdf

In vitro and in silico methods to predict cytochrome P450 enzyme inhibition

Abstract

Similar works

Full text

Available Versions

UEF Electronic Publications